Company news

InflaRx N.V. news in 2025

InflaRx N.V.'s news releases, calls and decks from 2025, newest first.

View company

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

December 30, 2025

InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904

December 11, 2025

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)

November 10, 2025

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

November 7, 2025

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

October 21, 2025

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

September 12, 2025

InflaRx Announces Participation in September Investor Conferences

August 21, 2025

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025

InflaRx to Report Second Quarter 2025 Results on August 7, 2025

July 31, 2025

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

July 11, 2025

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

May 28, 2025

InflaRx to Participate in Upcoming Investor Conferences

May 22, 2025

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025

InflaRx to Report First Quarter 2025 Results on May 7, 2025

April 30, 2025

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

March 20, 2025

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

March 7, 2025

InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

February 28, 2025

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

February 25, 2025

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

February 18, 2025

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

February 12, 2025

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

February 12, 2025

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

January 14, 2025

Decks in 2025